A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

Summary

This is a Phase 1/2, open-label, dose escalation and dose expansion study designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IBB0979 in previously treated patients with locally advanced or metastatic solid tumors.

Timeline

Start

2023-07-03

Primary completion

2025-11-30

Completion

2025-12-30

Drugs

Indications